ArticleScientific reports2026
Development and characterization of gelatin-platelet-rich plasma hydrogels for enhanced spinal cord injury repair.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) remains a major clinical challenge due to the limited regenerative capacity of the central nervous system. This study presents the development and characterization of a gelatin-platelet-rich plasma (PRP) hydrogel as a therapeutic strategy for SCI repair. A composite gelatin-PRP scaffold was fabricated by incorporating PRP into a gelatin matrix to enhance tissue regeneration and functional recovery. In vitro analyses demonstrated excellent biocompatibility, with neuronal cell viability increasing from 75% on Day 1 to 96% on Day 7 (p < 0.05). The release of growth factors including transforming growth factor β1 (TGF-β1), platelet-derived growth factor BB (PDGF-BB), and insulin-like growth factor 1 (IGF-1) followed a biphasic pattern, with approximately 85-88% released within 96 h (p < 0.05). In vivo, the PRP + Hydrogel group exhibited significantly improved locomotor recovery on the Basso-Beattie-Bresnahan (BBB) scale, along with reduced cavity formation, improved tissue preservation, and decreased scar-like tissue appearance compared with other treatments (n = 6 per group, p < 0.05). These findings indicate that gelatin-PRP hydrogels support growth factor delivery, promote tissue repair, and improve functional recovery, highlighting their potential as a biomaterial platform for spinal cord repair.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.